ReviewChemistry & biodiversity2026
Dual-Targeting Strategy in Cancer Therapy: The Emerging Role of Pyrrolopyrimidine Scaffolds.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pyrrolopyrimidine has emerged as a privileged scaffold in medicinal chemistry, owing to its synthesis with variable substitutions and the capacity to exhibit potent, diverse pharmacological profiles. In recent years, the development of dual-target agents has emerged as a research hotspot in cancer therapy, driven by their ability to overcome drug resistance, enhance pharmacokinetic and safety profiles, and improve patient compliance. The current review focuses on the concept of dual-targeted anticancer agents, with particular emphasis on pyrrolopyrimidine-based compounds capable of simultaneously modulating two distinct targets within cancer cells. Furthermore, it highlights resistance mechanisms, development strategies, target mechanisms, in vitro activity profiles, in vivo efficacy data, and available clinical findings, providing a comprehensive overview of their therapeutic potential and future prospects in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.